{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:39:14Z","timestamp":1790419154467,"version":"4.1.0"},"reference-count":61,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Favipiravir (T-705) has previously been shown to have a potent antiviral effect against influenza virus and some other RNA viruses in both cell culture and in animal models. Currently, favipiravir is undergoing clinical evaluation for the treatment of influenza A and B virus infections. In this study, favipiravir was evaluated<jats:italic>in vitro<\/jats:italic>for its ability to inhibit the replication of a representative panel of seasonal influenza viruses, the 2009 A(H1N1) strains, and animal viruses with pandemic (pdm) potential (swine triple reassortants, H2N2, H4N2, avian H7N2, and avian H5N1), including viruses which are resistant to the currently licensed anti-influenza drugs. All viruses were tested in a plaque reduction assay with MDCK cells, and a subset was also tested in both yield reduction and focus inhibition (FI) assays. For the majority of viruses tested, favipiravir significantly inhibited plaque formation at 3.2 \u03bcM (0.5 \u03bcg\/ml) (50% effective concentrations [EC<jats:sub>50<\/jats:sub>s] of 0.19 to 22.48 \u03bcM and 0.03 to 3.53 \u03bcg\/ml), and for all viruses, with the exception of a single dually resistant 2009 A(H1N1) virus, complete inhibition of plaque formation was seen at 3.2 \u03bcM (0.5 \u03bcg\/ml). Due to the 2009 pandemic and increased drug resistance in circulating seasonal influenza viruses, there is an urgent need for new drugs which target influenza. This study demonstrates that favipiravir inhibits<jats:italic>in vitro<\/jats:italic>replication of a wide range of influenza viruses, including those resistant to currently available drugs.<\/jats:p>","DOI":"10.1128\/aac.01739-09","type":"journal-article","created":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T03:55:06Z","timestamp":1269921306000},"page":"2517-2524","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":135,"title":["<i>In Vitro<\/i>Antiviral Activity of Favipiravir (T-705) against Drug-Resistant Influenza and 2009 A(H1N1) Viruses"],"prefix":"10.1128","volume":"54","author":[{"given":"Katrina","family":"Sleeman","sequence":"first","affiliation":[{"name":"Virus Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliy P.","family":"Mishin","sequence":"additional","affiliation":[{"name":"Virus Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varough M.","family":"Deyde","sequence":"additional","affiliation":[{"name":"Virus Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousuke","family":"Furuta","sequence":"additional","affiliation":[{"name":"Toyama Chemical Co., Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander I.","family":"Klimov","sequence":"additional","affiliation":[{"name":"Virus Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa V.","family":"Gubareva","sequence":"additional","affiliation":[{"name":"Virus Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0707279"},{"key":"e_1_3_2_3_2","unstructured":"FDAnews Drug Pipeline Alert 4. 2009"},{"key":"e_1_3_2_4_2","first-page":"433","volume":"58","year":"2009","unstructured":"Centers for Disease Control and Prevention. 2009. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, 2009. MMWR Morb. Mortal. Wkly. Rep.58:433-435.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_5_2","first-page":"692","volume":"57","year":"2008","unstructured":"Centers for Disease Control and Prevention. 2008. Influenza activity\u2014United States and worldwide, 2007-08 season. MMWR Morb. Mortal. Wkly. Rep.57:692-697.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_6_2","unstructured":"Flu activity and surveillance. 2009"},{"key":"e_1_3_2_7_2","unstructured":"Interim guidance on antiviral recommendations for patients with novel influenza A(H1N1) virus infection and their close contacts. 2009"},{"key":"e_1_3_2_8_2","first-page":"467","volume":"58","year":"2009","unstructured":"Centers for Disease Control and Prevention. 2009. Outbreak of swine-origin influenza A (H1N1) virus infection\u2014Mexico, March-April 2009. MMWR Morb. Mortal. Wkly. Rep.58:467-470.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_9_2","unstructured":"Seasonal influenza: the disease. 2009"},{"key":"e_1_3_2_10_2","first-page":"400","volume":"58","year":"2009","unstructured":"Centers for Disease Control and Prevention. 2009. Swine influenza A (H1N1) infection in two children\u2014Southern California, March-April 2009. MMWR Morb. Mortal. Wkly. Rep.58:400-402.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_11_2","first-page":"969","volume":"58","year":"2009","unstructured":"Centers for Disease Control and Prevention. 2009. Oseltamivir-resistant pandemic influenza A (H1N1) virus infection among summer camp attendees in the setting of liberal oseltamivir prophylaxis for influenza-like illness\u2014North Carolina, 2009. MMWR Morb. Mortal. Wkly. Rep.58:969-972.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_12_2","first-page":"893","volume":"58","year":"2009","unstructured":"Centers for Disease Control and Prevention. 2009. Oseltamivir-resistant novel influenza A (H1N1) virus infection in immunosuppressed patients receiving oseltamivir therapy. MMWR Morb. Mortal. Wkly. Rep.58:893-896.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1506.081357"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/504723"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.3.2.191"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.324_705"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0903810"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2007.04.005"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054512"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2008.08.008"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/518936"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.294"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.322.7286.577"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199921040-00003"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.4.977-981.2002"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.981-986.2005"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.02.198"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1176225"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.297"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01667-08"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)11433-8"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1086\/591851"},{"key":"e_1_3_2_33_2","first-page":"59","year":"1996","unstructured":"Hayden, F. G. 1996. Amantadine and rimantadine\u2014clinical aspects, p. 59-77. In D. D. Richman (ed.), Antiviral drug resistance. John Wiley and Sons Ltd., San Francisco, CA.","journal-title":"Antiviral drug resistance."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200005000-00005"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.03.003"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2006.10.004"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08260"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.2807\/ese.13.05.08026-en"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/4371108a"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.15.8418-8425.2003"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1309.070164"},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/135965350701200401","volume":"12","year":"2007","unstructured":"Medeiros, R., M. A. Rameix-Welti, V. Lorin, P. Ribaud, J. C. Manuguerra, G. Socie, C. Scieux, N. Naffakh, and S. van der Werf. 2007. Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus. Antivir. Ther.12:571-576.","journal-title":"Antivir. Ther."},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1504.181280"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.11.4515-4520.2005"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.03.046"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(03)00075-6"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.59.061506.213121"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0900648"},{"key":"e_1_3_2_49_2","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/nm1209","volume":"11","year":"2005","unstructured":"Plotkin, S. A. 2005. Vaccines: past, present and future. Nat. Med.11:S5-S11.","journal-title":"Nat. Med."},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.5.2164-2165.2003"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00555-08"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0903812"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp274"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm010528u"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08182"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1177\/095632020301400502"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1654(200001\/02)10:1<45::AID-RMV265>3.0.CO;2-R"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.324"},{"key":"e_1_3_2_59_2","unstructured":"What is phase 6? 2009"},{"key":"e_1_3_2_60_2","first-page":"41","volume":"82","year":"2009","unstructured":"World Health Organization. Accessed 27 October 2009. Update: WHO-confirmed human cases of avian influenza A(H5N1) infection, 25 November 2003-24 November 2006. Wkly. Epidemiol. Rec.82:41-47. http:\/\/www.who.int\/wer\/2007\/wer8206.pdf .","journal-title":"Wkly. Epidemiol. Rec."},{"key":"e_1_3_2_61_2","unstructured":"Influenza (seasonal). 2009"},{"key":"e_1_3_2_62_2","unstructured":"Pandemic (H1N1) 2009 - update 60. 2009"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01739-09","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01739-09","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T11:43:40Z","timestamp":1711367020000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01739-09"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1128\/AAC.01739-09"],"URL":"https:\/\/doi.org\/10.1128\/aac.01739-09","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"2009-12-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-02-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}